Introduction
Hormones are chemical messengers. In certain cancers they act as fuel — the tumour cells carry receptors that respond to a hormone and grow in response to it. Hormonal therapy, also called endocrine therapy, interrupts that relationship.
The National Cancer Institute describes two broad approaches: blocking the body from producing the hormone, or blocking the hormone from acting on the cancer cell.
It is used mainly in hormone-receptor-positive breast cancer and in prostate cancer, and the NCI notes it can shrink a tumour before surgery, lower the risk of the cancer returning, or treat cancer that has spread.
What sets hormonal therapy apart from most other cancer treatment is time. Where chemotherapy runs in cycles over months, endocrine therapy is often continued for five years or longer.
That changes the questions patients ask: not just does it work, but what will living with it be like.
At Athira, hormonal therapy is planned on the basis of receptor testing and reviewed by the multidisciplinary tumour board alongside surgery, radiation and any other systemic therapy. Because it runs long, the emphasis falls on managing side effects properly, protecting bone health where relevant, and keeping patients supported through years of treatment rather than only through the first few months.
Understanding Hormonal Therapy
Receptors
Some breast cancer cells carry oestrogen receptors, progesterone receptors, or both. These are described as hormone-receptor-positive. Most prostate cancers depend on androgens, principally testosterone. Where those receptors are present and active, the hormone is effectively driving growth.
Two ways to interrupt it
National Cancer Institute
Reduce hormone production
Drugs that suppress the body's manufacture of oestrogen or testosterone, or in some cases surgery or radiation to the glands that produce them.
Block hormone action
Drugs that occupy or disable the receptor so the hormone cannot deliver its signal, or that cause the receptor to be broken down.
In breast cancer
In breast cancer, the approach depends significantly on menopausal status, because the main source of oestrogen differs before and after menopause. This is why two patients with apparently similar breast cancers may be offered different endocrine drugs.
In prostate cancer
In prostate cancer, treatment aims to lower testosterone or block its effect. It may be given alone, alongside radiation, or in combination with other systemic agents depending on the stage.
Side effects follow from the mechanism
Lowering a hormone the body is used to produces predictable effects — hot flushes, mood and sleep changes, joint aches, reduced libido, and over time changes in bone density. Many are manageable, and some improve after the first months.
It is not chemotherapy
Endocrine therapy does not typically cause hair loss or the pattern of nausea and low blood counts associated with chemotherapy. Most patients take it as a daily tablet or receive a periodic injection while continuing normal life.
When Is Hormonal Therapy Recommended?
Hormonal therapy is only appropriate for cancers that depend on hormones. Whether it is recommended depends on receptor testing, the type and stage of the cancer, and — in breast cancer — menopausal status.
Your oncologist may consider it when:
Breast cancer testing shows oestrogen or progesterone receptor positivity
Prostate cancer requires androgen suppression as part of the treatment plan
A tumour may benefit from being shrunk before surgery, an approach the NCI notes hormonal therapy can be used for
Surgery and any other treatment are complete, and endocrine therapy is being given to lower the risk of recurrence
The cancer has spread and hormonal control is an appropriate systemic approach
Hormonal therapy is being combined with a targeted agent or with radiation as part of a defined regimen
A previous endocrine agent has stopped working and a different mechanism may still be effective
Hormone-receptor-negative cancers do not respond to this treatment, and it is not offered in those cases.
Diagnosis and Evaluation
Hormone receptor testing. For breast cancer, immunohistochemistry on the biopsy or surgical specimen determines oestrogen and progesterone receptor status. This single result determines whether endocrine therapy is even a possibility.
HER2 status, tested alongside, because it influences the overall systemic plan and whether a targeted agent is added.
Menopausal status assessment in breast cancer, which may require hormone level testing where it is not clinically obvious. This directly determines drug selection.
PSA and related assessment in prostate cancer, at baseline and then serially, as one of the main measures of response.
Testosterone levels, where monitoring the adequacy of androgen suppression is relevant.
Bone mineral density scan. Several endocrine treatments reduce bone density over time. A baseline DEXA scan, with periodic repeats, allows bone health to be protected rather than repaired.
Cardiovascular and metabolic baseline — blood pressure, lipids and glucose — particularly relevant with long-term androgen suppression.
Liver function and general blood work at baseline and periodically.
Gynaecological baseline and history where the planned agent makes it relevant, along with discussion of any history of blood clots.
Fertility and family planning discussion, before starting, for younger patients.
Treatment and Care Approaches
Adjuvant endocrine therapy
Taken after surgery, radiation and any chemotherapy, typically for five years or longer, to reduce recurrence risk. Duration is individualised according to risk.
Neoadjuvant endocrine therapy
Given before surgery to shrink a tumour — an option the NCI describes, and sometimes preferred where chemotherapy is less suitable.
Endocrine therapy for advanced disease
Used to control hormone-driven cancer that has spread, often over extended periods.
Combination with targeted agents
In several settings hormonal therapy is given alongside a targeted drug, with the combination and monitoring planned together.
Androgen deprivation therapy
In prostate cancer, by injection or implant, sometimes with an additional oral agent, and sometimes alongside radiation.
Ovarian suppression
Where the treatment plan for a premenopausal patient calls for it.
Bone health protection
Calcium and vitamin D guidance, weight-bearing exercise advice, periodic DEXA monitoring and bone-protective medication where indicated.
Symptom management
Practical strategies for hot flushes, sleep disturbance, joint stiffness and mood changes, with psycho-oncology support available.
Adherence support
Because benefit accrues over years, staying on treatment is part of the treatment. Difficulty tolerating a drug is a reason to come back and discuss it, not a reason to stop quietly.
Personalised Cancer Care at Athira
Endocrine therapy is a long relationship with a service, not a short course of treatment. Athira plans it that way.
Individualised drug selection
Drug selection is individualised from the start — receptor status, menopausal status, recurrence risk, bone density, cardiovascular profile and other medications all feed into the choice, and the reasoning is explained rather than assumed.
Duration is discussed openly
Extended treatment beyond five years benefits some patients and not others, and that decision is revisited with you at the appropriate point.
Side effects have solutions
Side effects are treated as clinical problems with solutions. Persistent joint pain, disruptive hot flushes or low mood are not something to endure silently for years. Often a switch within the same drug class, an adjustment in timing or specific supportive treatment makes a substantial difference — and it is far better than a patient stopping treatment without telling anyone.
Long-term health monitoring
Long-term health is monitored alongside the cancer. Bone density, cardiovascular risk and metabolic health all sit within the follow-up plan, because the point of years of treatment is a life worth living at the end of them.
Endocrine therapy is a long relationship with a service, not a short course of treatment. Athira plans it that way.
Why Athira
Receptor-led decisions
Hormonal therapy is offered only where testing shows the cancer is hormone-driven, consistent with NCI guidance on its use in breast and prostate cancer.
Integrated planning
Surgical and radiation oncology sit within the same team — Dr. Sarat Chandra Pingali leads surgical oncology and Dr. Madhusudhan N. radiation oncology — so endocrine therapy is sequenced within the whole plan.
Tumour board review
Systemic therapy decisions are made collectively, including the question of whether a targeted agent should be combined with endocrine treatment.
Long-term follow-up built in
The centre's care journey extends through recovery into survivorship care, which is precisely the period during which endocrine therapy continues.
Support for the human side
Psycho-oncology input is available within the wider team, and the effects of long-term hormonal treatment are taken seriously.
Experienced medical oncology leadership
Dr. Niti Krishna Raizada, Principal Director for Medical and Haemato-Oncology, holds MD, DNB, DM, ECMO, MRCP (UK) and EMPH (US) qualifications with 22 years in practice.
Frequently Asked Questions
How do I know if hormonal therapy will work for me?
It depends on receptor testing. In breast cancer, oestrogen and progesterone receptor status is tested on the biopsy or surgical specimen. In prostate cancer, the disease is generally androgen-dependent at the outset. If the cancer is receptor-negative, endocrine therapy is not offered.
How long will I need to take it?
Frequently five years, and sometimes longer depending on risk. In prostate cancer, duration varies widely with the stage and how it is combined with other treatment. Your oncologist will give you a planned duration and revisit it during follow-up.
Is hormonal therapy the same as chemotherapy?
No. They work in completely different ways and feel different to take. Endocrine therapy does not typically cause hair loss or the low blood counts associated with chemotherapy. Some patients receive both, at different stages of the plan.
What are the most common side effects?
Hot flushes, sleep disturbance, mood changes, joint or muscle aches, reduced libido and — over longer periods — reduced bone density. The specific pattern depends on the drug. Many effects settle somewhat after the first few months.
Will it affect my bones?
Several endocrine treatments reduce bone density over time. This is why a baseline DEXA scan and periodic monitoring are part of the plan, along with calcium and vitamin D guidance, exercise advice and bone-protective medication where indicated.
Can I stop if the side effects are difficult?
Please talk to your oncologist before stopping. There are often practical options — switching within the same class, changing when you take the dose, or adding specific supportive treatment. Stopping without discussion removes a benefit that builds over years.
Can hormonal therapy be given before surgery?
Yes. The National Cancer Institute notes hormonal therapy can be used to shrink a tumour before surgery. Whether that applies in your case depends on the tumour and the surgical plan.
Will it affect fertility or family planning?
It can, and in breast cancer treatment plans that include ovarian suppression this is a significant consideration. Raise it at your first consultation, while options are still open.
Does hormonal therapy mean I will not need chemotherapy?
Not necessarily. Some patients with hormone-receptor-positive cancer also benefit from chemotherapy, depending on stage and other tumour features. Additional testing sometimes helps clarify that decision, and it is discussed at the tumour board.
What happens if the cancer stops responding?
Hormone-driven cancers can become resistant to one agent while still responding to another mechanism. Switching within endocrine therapy, adding a targeted drug, or moving to a different approach are all possibilities your oncologist will discuss.
